Miramar

BBX Capital, Inc. Reports Financial Results For the Third Quarter of 2023

Retrieved on: 
Wednesday, November 8, 2023
Food, Beverage, Home Goods, Retail, Children, Urban Planning, Finance, Online Retail, Interior Design, Luxury, Consumer, Professional Services, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Vacation, Other Travel, Lodging, Travel, Sale, Toronto-Dominion Bank, Renin, NYSE, Tax, Miramar, OTCQX, Environment, Growth, Balance sheet, BBX Capital Corporation, TD, BBX, Investment, BVH, PINK, Renting, Security (finance), Video game, Renewable energy, Warehouse

BBX Capital, Inc. (OTCQX: BBXIA) (PINK: BBXIB) (“BBX Capital” or the “Company”) reported today its financial results for the third quarter of 2023.

Key Points: 
  • BBX Capital, Inc. (OTCQX: BBXIA) (PINK: BBXIB) (“BBX Capital” or the “Company”) reported today its financial results for the third quarter of 2023.
  • The following selected information relates to the financial results of the Company’s principal holdings: BBX Capital Real Estate, BBX Sweet Holdings, and Renin.
  • In connection with the transition, BBX Sweet Holdings acquired his noncontrolling interest in IT’SUGAR, and as a result, IT'SUGAR became a wholly-owned subsidiary of BBX Sweet Holdings during the three months ended September 30, 2023.
  • As of September 30, 2023, Renin was current on the payment terms under its TD Bank credit facility.

HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights

Retrieved on: 
Friday, November 12, 2021
Neurodegeneration, Primate, Degenerative disease, TMI, Prostate, HCW, G&A, Private Securities Litigation Reform Act, Breast, Clinical trial, Prospectus, R, Security (finance), NASDAQ, CEO, Technology, PCT, Inflammation, Food, Insurance, Strategic planning, Investment, Law on the fight against terrorism, Immunotherapy, Research, Forward-looking statement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual conferences, Intention, Public expenditure, National Cancer Institute, Board, AbbVie, Toxicology, Company, IPO, U.S. Securities and Exchange Commission, GLOBE, Conference, Colorectal cancer, Private law, Board of directors, SEC, Mouse, Investigational New Drug, Diabetes, Patient, Patent, FDA, IND, Pharmaceutical industry, Vaccine, Cryptocurrency

MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company or HCW Biologics) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its third quarter ended September 30, 2021.

Key Points: 
  • MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company or HCW Biologics) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its third quarter ended September 30, 2021.
  • The third quarter of 2021 and recent weeks were an important period for HCW Biologics and our strategy to build a pipeline of first-in-class immunotherapeutic treatments for age-related diseases, stated Hing C. Wong, Ph.D., founder and CEO of HCW Biologics Inc.
  • On July 22, 2021, HCW Biologics closed on its IPO, raising $56 million in gross proceeds.
  • HCW Biologics was added to S&P Total Market Index (TMI) on September 20, 2021.

HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer

Retrieved on: 
Thursday, October 28, 2021
Lung, Pancreatic cancer, Melanoma, HCW, American Cancer Society, Immunotherapy, Technology, Cancer, Disease, Neurodegeneration, Neoplasm, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, NASDAQ, FDA, Compte rendu, Degenerative disease, Food, Physical examination, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Forward-looking statement, Pancreas, Clinical trial, CEO, Inflammation, Pancreatic tumor, IND, Diabetes, Prospectus, Immune system, Therapy, GLOBE, Abdomen, Pharmaceutical industry

MIRAMAR, Fla., Oct. 28, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that it has been cleared by the U.S. Food and Drug Administration (FDA) to proceed to evaluate its lead drug candidate, HCW9218, in a first-in-human Phase 1b clinical trial in patients with advanced pancreatic cancer. HCW9218 is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities.

Key Points: 
  • Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, stated, "The FDAs clearance to proceed with our first-in-human trial for HCW9218 in pancreatic cancer is an important milestone for HCW Biologics and our efforts to advance the development of potentially groundbreaking immunotherapy candidates for cancer and other age-related diseases.
  • Pancreatic cancer develops when anomalous cells in the pancreas grow and divide out of control to form a tumor.
  • The invention of HCW Biologics two lead molecules, HCW9218 and HCW9302, was made via the TOBI discovery platform.
  • The FDA has cleared HCW Biologics to initiate a first-in-human Phase 1b clinical trial for HCW9218 in patients with advanced pancreatic cancer.

HCW Biologics Announces Appointment of Two New Members to Board of Directors

Retrieved on: 
Wednesday, October 27, 2021
Immunotherapy, Northwestern University, Board of directors, U.S. Securities and Exchange Commission, Compte rendu, Stanford University, Degenerative disease, Monsanto, Strategic planning, Inflammation, IND, Health, Prospectus, Therapy, Autoimmunity, GLOBE, Academic health science centre, Security (finance), Abbott Laboratories, Private Securities Litigation Reform Act, Infection, Divisional Railway Hospital, Golden Rock, AbbVie, GAC, Company, MIST, Industry, SEC, Leadership, Chicago (franchise), CEO, Diabetes, Sale, HCW, Technology, University, Cancer, Knowledge, Neurodegeneration, Board, Patient, California State University, NASDAQ, Corporation, Forward-looking statement, Juniata College, Director, Pharmaceutical industry, Management

On behalf of the Board, I am pleased to welcome them to HCW Biologics and look forward to benefitting from their knowledge and expertise.

Key Points: 
  • On behalf of the Board, I am pleased to welcome them to HCW Biologics and look forward to benefitting from their knowledge and expertise.
  • Dr. Wong will step down from the audit committee but remain a member of the Board of Directors.
  • I look forward to working with Dr. Wong, the leadership team and the other Board members as HCW advances its clinical development portfolio.
  • Mr. Winer commented, I am eager to work with Dr. Wong and the other Board members to help HCW Biologics achieve its full potential.

Stemtech Corporation Launches “Healthy Goals” Initiative Supporting Healthy, Active Communities: Sponsors Youth Soccer League Event

Retrieved on: 
Monday, October 25, 2021
Dentistry, Juventus F.C., Goal, Dietary Supplement Health and Education Act of 1994, Security (finance), Private Securities Litigation Reform Act, Human, CGMP, Policy, Government, Leadership, Time, DSHEA, Social media, Adult, B cell, Company, CEO, OTC, Bone marrow, Health, GLOBE

MIRAMAR, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTC: GNTW), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that it has launched its Healthy Goals social initiative.

Key Points: 
  • MIRAMAR, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTC: GNTW), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that it has launched its Healthy Goals social initiative.
  • The first sponsorship of the initiative is a youth soccer league event in Miami, Florida called the Juventus Juve Cup.
  • Stemtech is taking action to support healthy, active communities, said Charles S. Arnold, Chairman and CEO of Stemtech.
  • We will continue to foster our Healthy Goals social initiative with a variety of sponsorships, including Juventus.

Stemtech Corporation (OTC:GNTW) Announces Appointment of John W. Meyer to Role of President and COO

Retrieved on: 
Tuesday, October 19, 2021
Dentistry, Government, Policy, Director, Dietary Supplement Health and Education Act of 1994, Business, DSHEA, CGMP, Income, Arbonne International, Growth, Security (finance), B cell, OTC, Shaklee, Adult, Board, Leadership, Time, CEO, GLOBE, Private Securities Litigation Reform Act, COO, Patent, Marketing, Company, Bone marrow, Management

Mr. Meyer joined Stemtech in 2006 and oversees all global operations.

Key Points: 
  • Mr. Meyer joined Stemtech in 2006 and oversees all global operations.
  • His responsibilities now include the role of President, where he will lead all aspects of Stemtech, reporting to CEO Charles S. Arnold and the Board of Directors.
  • All functional departments and international operations are his responsibility to drive growth and expansion of the company.
  • Prior to joining Stemtech, John worked for other well-known network marketing companies, such as Shaklee and Arbonne International for over ten years.

Stemtech Corporation Announces Appointment of Two Additional Board Members

Retrieved on: 
Wednesday, October 6, 2021
Dietary Supplement Health and Education Act of 1994, Patent, GNC (store), Policy, GNC, OTC, Bone marrow, Therapy, CGMP, Health, Security (finance), Patient, DSHEA, Adult, Board, CEO, Private Securities Litigation Reform Act, Company, Leadership, IPO, B cell, Government, Dentistry, Industry, Time, GLOBE, Pharmaceutical industry

MIRAMAR, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTC: GNTW), a leading nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that it has appointed two new Board members, Darryl Green and Benjamin Kaplan, bringing the total number of Stemtech Directors to five.

Key Points: 
  • MIRAMAR, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTC: GNTW), a leading nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that it has appointed two new Board members, Darryl Green and Benjamin Kaplan, bringing the total number of Stemtech Directors to five.
  • We are proud to welcome Darryl Green and Benjamin Kaplan to the Board, said Charles Arnold, Chairman and CEO of Stemtech.
  • The Stemtech board now consists of Charles Arnold, Chairman and CEO, John W. Meyer COO, John JT Thatch, Darryl Green and Benjamin Kaplan.
  • Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005.

Stemtech Corporation to Present at the Emerging Growth Conference on Wednesday, September 29, 2021

Retrieved on: 
Tuesday, September 28, 2021
Dietary Supplement Health and Education Act of 1994, Policy, Bone marrow, Security (finance), CGMP, Conference, DSHEA, Adult, Growth, Private Securities Litigation Reform Act, Investment, Company, Leadership, B cell, Government, Time, Dentistry, GLOBE, Medicine, Broadcasting, Risk management

MIRAMAR, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation (Symbol: GNTW), a leading nutraceutical company and a pioneer in the field of stem cell nutrition, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, September 29, 2021.

Key Points: 
  • MIRAMAR, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation (Symbol: GNTW), a leading nutraceutical company and a pioneer in the field of stem cell nutrition, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, September 29, 2021.
  • The Emerging Growth Conference is a live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Companys COO, John W. Meyer, in real time.
  • Click the link to register for free conference attendance:
    Please register here to ensure you are able to attend the conference and receive any updates that are released.
  • The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth.

Stemtech Corporation Receives Strategic Funding From Leading Company in Direct-to-Consumer Sector

Retrieved on: 
Tuesday, September 21, 2021
Dietary Supplement Health and Education Act of 1994, MSRB, OTCQB, Policy, Employment, Bone marrow, Security (finance), CGMP, Board of directors, NASDAQ, Transport, Capital market, SIPC, SHRG, DSHEA, Adult, Board, Marketing, Private Securities Litigation Reform Act, CEO, Bank, Acquisition, Company, LLC, Private sector, FINRA, Leadership, Technology, B cell, Government, Time, Dentistry, Industry, Education, GLOBE, Management, Cryptocurrency

Stemtech is proud to receive funding from Sharing Services Global Corporation as a strategic investment, said Charles Arnold, Chairman and CEO of Stemtech.

Key Points: 
  • Stemtech is proud to receive funding from Sharing Services Global Corporation as a strategic investment, said Charles Arnold, Chairman and CEO of Stemtech.
  • As part of the transaction, John JT Thatch, the CEO of Sharing Services Global Corporation will join Stemtech Corporation as a member of its Board of Directors.
  • Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005.
  • Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

360Wise Spotlights Congresswoman Sheila Jackson Lee On Gospel Music Heritage Month in America

Retrieved on: 
Thursday, September 16, 2021
Stellar, European Union, Madrid Protocol of 1885, Macdonald, Gospel Music Heritage Month, Madrid system, European Union Intellectual Property Office, Gospel music, Bobby Jones (singer), Marketing, White House, Television, Advertising, Public relations, John F. Kennedy Center for the Performing Arts, Quote, Music, International Trademark Association, Lisbon Agreement for the Protection of Appellations of Origin and their International Registration, Good, Good news, MC Hammer, National, Heritage, GLOBE, American Music, Mark (given name), History, Host, Media, Television presenter, Life, News, McDonald's Gospelfest, Film, Entertainment

MIAMI, Sept. 16, 2021 (GLOBE NEWSWIRE) -- The Gospel Music Heritage Month Foundation was established years ago to celebrate and educate people everywhere about the rich heritage of the gospel music genre through word and song by Gospel Music Advocate Carl Davis.

Key Points: 
  • MIAMI, Sept. 16, 2021 (GLOBE NEWSWIRE) -- The Gospel Music Heritage Month Foundation was established years ago to celebrate and educate people everywhere about the rich heritage of the gospel music genre through word and song by Gospel Music Advocate Carl Davis.
  • In 2008, Congresswoman Sheila Jackson Lee (D-TX) and Senator Blanche Lincoln (D-AR) led the passing of a resolution in both chambers declaring September as Gospel Music Heritage Month.
  • Congresswoman Sheila Jackson Lee has successfully led efforts since 2008 to ensure the contributions, history, and sound of Gospel music are recognized and honored throughout the nation by passing resolutions that designate September as Gospel Music Heritage Month.
  • We appreciate the dynamic efforts of Congresswoman Sheila Jackson Lee in helping to establish Gospel Music Heritage month.